Common Names
Geographic Range: East Asia — China, Japan, Korea, Mongolia, Siberia.
Known Contraindications
1
Compounds
2
Traditions
4
Treatments
7
Conditions
O=C(OC[C@]12C[C@@H](OC(=O)c3ccccc3)[C@H](O1)[C@@H]1OC(CO)[C@@H](O)[C@H](O)[C@@H]1O)C2CYP Interaction Profile
| Enzyme | Interaction |
|---|---|
| CYP1A2 | no significant interaction |
| CYP2C9 | no significant interaction |
| CYP2D6 | no significant interaction |
| CYP3A4 | weak substrate (minor hepatic metabolism) |
| CYP2C19 | no significant interaction |
| clinical_note | Gut flora-dependent activation. Antibiotic co-administration may reduce therapeutic effect. Low direct CYP interaction risk. |
| gut_flora_note | Primary metabolism via gut flora hydrolysis to paeonimetabolin I/II. Concurrent antibiotic use may significantly reduce efficacy. |